DMTK DermTech, Inc. Stock Quote

DMTK [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	6.30%	Shs Outstand	18.93M	Perf Week	20.76%
Market Cap	982.93M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	15.11%	Shs Float	4.93M	Perf Month	200.15%
Income	-30.90M	PEG	-	EPS next Q	-0.57	Inst Own	48.10%	Short Float	23.64%	Perf Quarter	262.38%
Sales	5.40M	P/S	182.02	EPS this Y	17.10%	Inst Trans	1.44%	Short Ratio	1.98	Perf Half Y	277.21%
Book/sh	2.76	P/B	14.69	EPS next Y	2.30%	ROA	-58.40%	Target Price	36.33	Perf Year	255.39%
Cash/sh	2.12	P/C	19.09	EPS next 5Y	-	ROE	-65.00%	52W Range	8.69 - 42.71	Perf YTD	25.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-133.40%	52W High	-5.06%	Beta	1.00
Dividend %	-	Quick Ratio	13.30	Sales past 5Y	-	Gross Margin	-2.00%	52W Low	366.63%	ATR	3.95
Employees	60	Current Ratio	13.30	Sales Q/Q	133.30%	Oper. Margin	-	RSI (14)	75.71	Volatility	9.99% 15.11%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	38.20%	Profit Margin	-	Rel Volume	1.65	Prev Close	39.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	587.29K	Price	40.55
Recom	1.70	SMA20	35.77%	SMA50	107.06%	SMA200	187.65%	Volume	970,545	Change	3.97%

Dec-14-20

Initiated

Craig Hallum

Buy

$23

Oct-30-20

Initiated

William Blair

Outperform

Dec-05-19

Initiated

Lake Street

Buy

Jan-19-21 04:30PM	DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 Business Wire
Jan-14-21 04:30PM	DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry Business Wire
Jan-12-21 04:01PM	DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines Business Wire +10.18%
Jan-11-21 04:01PM	DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jan-07-21 12:00AM	DermTech Announces Pricing of Public Offering of Common Stock Business Wire +10.78%
Jan-06-21 04:01PM	DermTech Announces Proposed Public Offering of Common Stock Business Wire +8.20%
Jan-05-21 04:30PM	DermTech Announces Appointment of General Counsel Business Wire
02:27PM	Here's Why You Should Really Own DermTech Stock in 2021 Motley Fool
Dec-30-20 04:22PM	5 Top Stock Gainers for Wednesday: Bilibili, DermTech TheStreet.com +27.42%
11:13AM	Why DermTech Stock Is Soaring Today Motley Fool
08:08AM	The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga
Dec-29-20 05:05PM	DermTech Receives Positive Medical Coverage by Geisinger Health System Business Wire +10.36%
Dec-28-20 04:01PM	DermTech Management to Present at the ICR Conference 2021 Business Wire
08:30AM	DermTech (DMTK) in Focus: Stock Moves 6% Higher Zacks
Dec-23-20 03:24PM	Why DermTech Stock Soared Today Motley Fool +13.26%
Dec-17-20 04:30PM	DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% and Find No Significant Adverse Outcomes After Long-Term Follow-Up of PLA Negative Tests Business Wire +5.85%
Dec-11-20 09:00AM	DermTechs Melanoma Test Included in Two Continuing Medical Education ("CME") Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium Business Wire
Dec-10-20 04:01PM	DermTech Enters Into Agreement With Blue Shield of California Business Wire
Dec-03-20 04:30PM	DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit Business Wire
Dec-02-20 10:14PM	Is DermTech (DMTK) A Good Stock To Buy Now? Insider Monkey
Nov-20-20 08:00AM	DermTech Enters Agreement with Blue Cross Blue Shield of Illinois Business Wire +5.46%
Nov-17-20 04:30PM	DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference Business Wire
Nov-13-20 06:08AM	Buying These 3 Stocks Could Make You Rich Over the Next Decade Motley Fool
Nov-10-20 04:01PM	DermTech Reports Third Quarter 2020 Financial Results Business Wire
Nov-04-20 04:01PM	DermTech to Participate in Upcoming Investor Conferences Business Wire
Oct-27-20 04:01PM	DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020 Business Wire
09:00AM	SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of DermTech, Inc. - DMTK ACCESSWIRE
Oct-26-20 06:38PM	3 Healthcare Stocks to Watch Motley Fool
Sep-14-20 08:51AM	What You Need To Know About DermTech, Inc.'s (NASDAQ:DMTK) Investor Composition Simply Wall St.
Sep-10-20 09:31AM	Benzinga's Top Upgrades, Downgrades For September 10, 2020 Benzinga
Sep-08-20 08:00AM	DermTech Announces Appointment of Chief Scientific Officer Business Wire -7.27%
Sep-03-20 04:01PM	DermTech to Participate in Upcoming Investor Conferences Business Wire
Aug-05-20 04:01PM	DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Jun-30-20 08:00AM	DermTech Announces Inclusion in the Russell 2000 Index Business Wire
Jun-16-20 06:40AM	Here's Why We're Not Too Worried About DermTech's (NASDAQ:DMTK) Cash Burn Situation Simply Wall St.
Jun-10-20 03:27PM	Here is What Hedge Funds Think About DermTech, Inc. (DMTK) Insider Monkey -5.61%
May-20-20 04:30PM	DermTech PLA Included in Peer Review Article of Novel Molecular Technologies for Melanoma Management with Potential to Address Current Gaps in Diagnostic Accuracy and Prognostication Business Wire
May-13-20 04:01PM	DermTech, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update Business Wire
May-11-20 05:00PM	Proof-of-Concept Research Demonstrates Patients Reliably Perform Remote Self-Sampling of Concerning Moles Using DermTechs Non-Invasive Adhesive Skin Collection Kit Under Physician Supervision via Telemedicine Business Wire
May-05-20 09:15AM	The Melanoma Research Foundation Hosting Weekly Facebook Live Ask a Dermatologist Sessions throughout Melanoma Awareness Month Business Wire
Apr-30-20 04:41PM	DermTech Announces Telemedicine Solution to Enable Remote Use of its Non-Invasive Adhesive Patch Test for Melanoma Detection Business Wire
Mar-25-20 08:00AM	DermTech Announces Response to COVID-19 Business Wire
Mar-16-20 09:33AM	New Study Shows Combining TERT Mutation Analyses With DermTechs PLA Provides Improved Sensitivity for Detecting Melanoma With Non-invasive Patches Business Wire -17.66%
Mar-10-20 04:01PM	DermTech, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire
Mar-05-20 08:00AM	Large Registry Study Demonstrates Clinicians Use DermTechs Non-Invasive Gene Expression Testing to Improve Early Melanoma Detection Business Wire
Mar-03-20 04:05PM	DermTech to Participate at the 2020 BTIG Healthcare Conference Business Wire +22.92%
Mar-02-20 06:00AM	DermTech Announces $65 Million Private Placement Business Wire +8.60%
Feb-11-20 05:29PM	DermTech to Present at Upcoming Investor Conferences Business Wire
Feb-10-20 03:06PM	Cowens Tim Manning at 2nd SPAC Roundtable: Fundamental Investor Interest in SPACs On Rise IPO-Edge.com
Jan-16-20 05:45PM	DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay Business Wire
Jan-08-20 08:00AM	CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTechs Pigmented Lesion Assay (PLA) Business Wire -10.88%
Jan-02-20 08:00AM	DermTechs Pigmented Lesion Assay (PLA) Receives Medicare Coverage Business Wire
Nov-07-19 01:30PM	DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire +6.89%
Nov-06-19 02:28PM	DermTech to Present at Upcoming Investor Conferences Business Wire
Oct-28-19 08:00AM	DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association Business Wire
Oct-22-19 08:00AM	DermTech Presents New Data at Fall Clinical Dermatology Conference Business Wire -9.28%
Oct-18-19 04:15PM	DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market Business Wire
Oct-15-19 08:00AM	DermTechs Test Included in Expert Panels Clinical Management Recommendations for Cutaneous Melanoma Business Wire
Oct-07-19 08:00AM	DermTech Further Expands Patent Portfolio Business Wire
Sep-16-19 04:30PM	DermTech Announces Appointment of Kevin Sun as Chief Financial Officer Business Wire

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Posard Matthew L.	Director	Jan 11	Buy	29.50	33,898	999,991	86,863	Jan 13 04:21 PM
RTW INVESTMENTS, LP	10% Owner	Jan 07	Buy	29.50	200,000	5,900,000	3,087,216	Jan 11 06:04 PM
PANCOAST SCOTT R	Director	Dec 14	Sale	13.93	6,000	83,569	44,132	Dec 16 04:40 PM
Jansen Burkhard	Chief Medical Officer	Dec 14	Sale	12.41	5,000	62,050	79,037	Dec 16 04:36 PM
Jansen Burkhard	Chief Medical Officer	Dec 11	Sale	12.20	5,000	61,000	74,037	Dec 17 08:11 PM
Wood Todd Michael	Chief Commercial Officer	Dec 08	Sale	11.86	428	5,076	165,199	Dec 10 04:10 PM
Ibarra Claudia	Chief Operating Officer	Dec 08	Sale	11.86	2,421	28,713	115,246	Dec 10 04:08 PM
Dobak John	Chief Executive Officer	Dec 08	Sale	11.86	786	9,322	541,683	Dec 10 04:06 PM
PANCOAST SCOTT R	Director	Dec 07	Sale	12.00	2,382	28,584	50,132	Dec 09 04:44 PM
Jacobs Gary E.	Director	Oct 26	Option Exercise	1.08	692	747	523,903	Oct 28 04:11 PM
Wood Todd Michael	Chief Commercial Officer	Sep 10	Sale	10.82	1,345	14,558	165,627	Sep 14 07:38 PM
Dobak John	Chief Executive Officer	Sep 10	Sale	10.82	2,470	26,735	542,469	Sep 14 07:36 PM
Ibarra Claudia	Chief Operating Officer	Sep 10	Sale	10.82	7,605	82,316	117,667	Sep 14 07:34 PM
Posard Matthew L.	Director	Apr 29	Option Exercise	6.94	9,702	67,332	44,965	May 01 04:24 PM
RTW INVESTMENTS, LP	10% Owner	Apr 01	Buy	10.41	26,539	276,316	2,627,268	Apr 01 05:05 PM
RTW INVESTMENTS, LP	10% Owner	Mar 31	Buy	11.26	5,000	56,321	2,600,729	Apr 01 05:05 PM
RTW INVESTMENTS, LP	10% Owner	Mar 05	Buy	14.61	23,955	350,088	2,595,729	Mar 05 05:10 PM
RTW INVESTMENTS, LP	10% Owner	Mar 04	Buy	14.75	4,447	65,593	2,571,774	Mar 05 05:10 PM
RTW INVESTMENTS, LP	10% Owner	Mar 03	Buy	14.52	13,000	188,713	2,567,327	Mar 05 05:10 PM
PANCOAST SCOTT R	Director	Mar 02	Option Exercise	1.12	10,640	11,917	44,514	Mar 04 04:17 PM
RTW INVESTMENTS, LP	10% Owner	Mar 02	Buy	12.83	15,000	192,428	2,554,327	Mar 03 11:09 AM
Picozza Enrico	Director	Feb 28	Buy	10.50	76,228	800,394	691,613	May 29 04:13 PM
RTW INVESTMENTS, LP	10% Owner	Feb 28	Buy	10.50	152,456	1,600,788	2,539,327	Mar 03 11:09 AM
PANCOAST SCOTT R	Director	Feb 07	Option Exercise	1.08	3,990	4,309	33,874	Feb 11 04:09 PM
PANCOAST SCOTT R	Director	Feb 05	Option Exercise	1.08	3,990	4,309	29,884	Feb 07 04:17 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience